谢谢RADOR, 不知这个增发影响有多大?
Public Offering of Common Stock
Amicus Therapeutics, Inc. 22 hours ago GlobeNewswire
CRANBURY, N.J., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics (FOLD)
, a biopharmaceutical company at the forefront of therapies for rare and
orphan diseases, today announced it has commenced a $75 million underwritten
public offering of its common stock. J.P. Morgan Securities LLC is acting
as sole book-running manager for the proposed offering. Cowen and Company,
LLC and Leerink Partners are acting as lead managers and Janney Montgomery
Scott is acting as co-manager for the offering. The Company expects to grant
the underwriters a 30-day option to purchase up to an additional 15% of the
shares of common stock offered in the public offering. The offering is
subject to market conditions, and there can be no assurance as to whether or
when the offering may be completed, or as to the final size or terms of the
offering.
The Company expects to use the net proceeds of the offering for investment
in the global commercialization infrastructure for migalastat monotherapy
for Fabry disease, the continued clinical development of its product
candidates and for other general corporate purposes.
The securities described above are being offered by Amicus pursuant to a
registration statement previously filed and declared effective by the
Securities and Exchange Commission (the "SEC"). A preliminary prospectus
supplement relating to the offering will also be filed with the SEC. Copies
of the preliminary prospectus supplement and accompanying base prospectus
relating to the offering may be obtained by contacting J.P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, New York 11717 (telephone number: 866-803-9204).
This press release does not constitute an offer to sell or a solicitation of
an offer to buy the securities described herein, nor shall there be any
sale of these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction.